Protective effect of melatonin on TNF-α-induced muscle atrophy in L6 myotubes

Journal of Pineal Research

Volumn 54, Issue 4, 2013, Pages 417-425

  Park, Jae Hyung ^a   Chung, Eun Ji ^a   Kwon, Hae Jung ^a   Im, Seung Soon ^a   Lim, Jung Geun ^a   Song, Dae Kyu ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Antioxidant enzyme activity; L6 myotube; Melatonin; Muscle atrophy; Muscle cell death; Reactive oxygen species; TNF

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATROGIN 1; CATALASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; MEMBRANE RECEPTOR; MUSCLE RING FINGER 1 PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SUPEROXIDE DISMUTASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; HYPOTROPHY; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; MUSCLE ATROPHY; MUSCLE NECROSIS; MYOTUBE; NONHUMAN; OXIDATIVE STRESS; PROTECTION; PROTEIN DEGRADATION; RAT; WESTERN BLOTTING;

ANTIOXIDANT ENZYME ACTIVITY; L6 MYOTUBE; MELATONIN; MUSCLE ATROPHY; MUSCLE CELL DEATH; REACTIVE OXYGEN SPECIES; TNF-Α;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; MELATONIN; MUSCULAR ATROPHY; RATS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879462685     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12036     Document Type: Article

References (72)

1. ACHARYYA S, LADNER KJ, NELSEN LL et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114:370-378.
2. DOYLE A, ZHANG G, ABDEL FATTAH EA et al. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J 2011; 25:99-110.
3. STRASSMANN G, FONG M, KENNEY JS, JACOB CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89:1681-1684.
4. ZAMIR O, O'BRIEN W, THOMPSON R et al. Reduced muscle protein breakdown in septic rats following treatment with interleukin-1 receptor antagonist. Int J Biochem 1994; 26:943-950.
5. SISHI BJ, ENGELBRECHT AM. Tumor necrosis factor alpha (TNF-alpha) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine 2011; 54:173-184.
6. KIRILLOVA I, CHAISSON M, FAUSTO N. Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. Cell Growth Differ 1999; 10:819-828.
7. SCHUTZE S, MACHLEIDT T, KRONKE M. Mechanisms of tumor necrosis factor action. Semin Oncol 1992; 19:16-24.
8. BASU A, JOHNSON DE, WOOLARD MD. Potentiation of tumor necrosis factor-alpha-induced cell death by rottlerin through a cytochrome-C-independent pathway. Exp Cell Res 2002; 278:209-214.
9. EL-NAGGAR EA, KANDA F, OKUDA S et al. Direct effects of tumor necrosis factor alpha (TNF-alpha) on L6 myotubes. Kobe J Med Sci 2004; 50:39-46.
10. LI YP. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 2003; 285:C370-C376.
11. LI YP, REID MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1165-R1170.
12. BLAKE DJ, WEIR A, NEWEY SE, DAVIES KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82:291-329.
13. HOPF FW, TURNER PR, STEINHARDT RA. Calcium misregulation and the pathogenesis of muscular dystrophy. Subcell Biochem 2007; 45:429-464.
14. GAILLY P, DE BACKER F, VAN SCHOOR M, GILLIS JM. In situ measurements of calpain activity in isolated muscle fibres from normal and dystrophin-lacking mdx mice. J Physiol 2007; 582:1261-1275.
15. STEHLE JH, SAADE A, RAWASHDEH O et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res 2011; 51:17-43.
16. PETROSILLO G, COLANTUONO G, MORO N et al. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol 2009; 297:H1487-H1493.
17. TENGATTINI S, REITER RJ, TAN DX et al. Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44:16 -25.
18. ERKANLI K, KAYALAR N, ERKANLI G et al. Melatonin protects against ischemia/reperfusion injury in skeletal muscle. J Pineal Res 2005; 39:238-242.
19. WANG WZ, FANG XH, STEPHENSON LL et al. Melatonin reduces ischemia/reperfusion-induced superoxide generation in arterial wall and cell death in skeletal muscle. J Pineal Res 2006; 41:255-260.
20. YEUNG HM, HUNG MW, FUNG ML. Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. J Pineal Res 2008; 45:373-382.
21. ESCAMES G, LOPEZ LC, TAPIAS V et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006; 40:71-78.
22. HIBAOUI Y, ROULET E, RUEGG UT. Melatonin prevents oxidative stress-mediated mitochondrial permeability transition and death in skeletal muscle cells. J Pineal Res 2009; 47:238-252.
23. KIM CH, KIM KH, YOO YM. Melatonin protects against apoptotic and autophagic cell death in C2C12 murine myoblast cells. J Pineal Res 2011; 50:241-249.
24. HIBAOUI Y, REUTENAUER-PATTE J, PATTHEY-VUADENS O et al. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy. J Pineal Res 2011; 51:163-171.
25. STRATOS I, RICHTER N, ROTTER R et al. Melatonin restores muscle regeneration and enhances muscle function after crush injury in rats. J Pineal Res 2012; 52:62-70.
26. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
27. HARDELAND R, TAN DX, REITER RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47:109-126.
28. URATA Y, HONMA S, GOTO S et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27:838-847.
29. RODRIGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
30. GARCIA-MACIA M, VEGA-NAREDO I, DE GONZALO-CALVO D et al. Melatonin induces neural SOD2 expression independent of the NF-kappaB pathway and improves the mitochondrial population and function in old mice. J Pineal Res 2011; 50:54 -63.
31. PARADIES G, PETROSILLO G, PARADIES V et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48:297-310.
32. KABEYA Y, MIZUSHIMA N, UENO T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19:5720-5728.
33. RUBINSZTEIN DC, GESTWICKI JE, MURPHY LO, KLIONSKY DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6:304-312.
34. JIN B, LI YP. Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. J Cell Biochem 2007; 100:960-969.
35. GOMES MD, LECKER SH, JAGOE RT et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98:14440-14445.
36. LI YP, CHEN Y, LI AS, REID MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003; 285:C806-C812.
37. SACHECK JM, OHTSUKA A, MCLARY SC, GOLDBERG AL. IGFI stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-E601.
38. SMITH MA, MOYLAN JS, SMITH JD et al. IFN-gamma does not mimic the catabolic effects of TNF-alpha. Am J Physiol Cell Physiol 2007; 293:C1947-C1952.
39. WRAY CJ, MAMMEN JM, HERSHKO DD, HASSELGREN PO. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 2003; 35:698-705.
40. DE PALMA L, MARINELLI M, PAVAN M, ORAZI A. Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy. Joint Bone Spine 2008; 75:53-57.
41. SALANOVA M, SCHIFFL G, PUTTMANN B et al. Molecular biomarkers monitoring human skeletal muscle fibres and microvasculature following long-term bed rest with and without countermeasures. J Anat 2008; 212:306-318.
42. LEVINE S, NGUYEN T, TAYLOR N et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008; 358:1327-1335.
43. WING SS, LECKER SH, JAGOE RT. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Crit Rev Clin Lab Sci 2011; 48:49-70.
44. VENTADOUR S, ATTAIX D. Mechanisms of skeletal muscle atrophy. Curr Opin Rheumatol 2006; 18:631-635.
45. LI H, MALHOTRA S, KUMAR A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) 2008; 86:1113-1126.
46. ROUBENOFF R, ROUBENOFF RA, WARD LM et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19:1505-1510.
47. TRACEY KJ, CERAMI A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9:317-343.
48. LANGEN RC, SCHOLS AM, KELDERS MC et al. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol 2002; 283:C714-C721.
49. FONG Y, MOLDAWER LL, MARANO M et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256:R659-R665.
50. FLORES EA, BISTRIAN BR, POMPOSELLI JJ et al. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1. J Clin Invest 1989; 83:1614-1622.
51. SPIEGELMAN BM, HOTAMISLIGIL GS. Through thick and thin: wasting, obesity, and TNF alpha. Cell 1993; 73:625-627.
52. JAGOE RT, GOLDBERG AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4:183-190.
53. GOOSSENS V, GROOTEN J, DE VOS K, FIERS W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci U S A 1995; 92:8115-8119.
54. LI X, MOODY MR, ENGEL D et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000; 102:1690-1696.
55. GARG AK, AGGARWAL BB. Reactive oxygen intermediates in TNF signaling. Mol Immunol 2002; 39:509-517.
56. REID MB, LI YP. Cytokines and oxidative signalling in skeletal muscle. Acta Physiol Scand 2001; 171:225-232.
57. LI YP, REID MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 2001; 13:483-487.
58. GARCIA-MARTINEZ C, AGELL N, LLOVERA M et al. Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett 1993; 323:211-214.
59. LI YP, LECKER SH, CHEN Y et al. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 2003; 17:1048-1057.
60. GLASS DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003; 5:87-90.
61. GLASS DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37:1974-1984.
62. GOMES-MARCONDES MC, TISDALE MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett 2002; 180:69-74.
63. WAJANT H, PFIZENMAIER K, SCHEURICH P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10:45-65.
64. TAN DX, REITER RJ, MANCHESTER LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2:181-197.
65. HARDELAND R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27:119-130.
66. TAN DX, MANCHESTER LC, TERRON MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42:28-42.
67. BONNEFONT-ROUSSELOT D, COLLIN F, JORE D, GARDES-ALBERT M. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50:328-335.
68. ROBERTS JE, HU DN, WISHART JF. Pulse radiolysis studies of melatonin and chloromelatonin. J Photochem Photobiol, B 1998; 42:125-132.
69. SHIDA CS, CASTRUCCI AM, LAMY-FREUND MT. High melatonin solubility in aqueous medium. J Pineal Res 1994; 16:198-201.
70. BONNEFONT-ROUSSELOT D, COLLIN F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010; 278:55-67.
71. VENEGAS C, GARCIA JA, ESCAMES G et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52:217-227.
72. FORMAN K, VARA E, GARCIA C et al. Beneficial effects of melatonin on cardiological alterations in a murine model of accelerated aging. J Pineal Res 2010; 49:312-320.